Bob joined us as chief financial officer in September 2017. Prior to joining Unity, Bob was chief financial officer of CytomX Therapeutics from 2015 until 2017. As CFO of CytomX, he led efforts related to the company’s mezzanine financing and IPO. Prior to CytomX, Mr. Goeltz was CFO of Onyx Pharmaceuticals, Inc. after its acquisition by Amgen, Inc. in 2013. From 2004 to 2013, Mr. Goeltz held leadership roles in Business Development, Commercial Finance, R&D Finance and Corporate Accounting at Amgen, Inc.. Mr. Goeltz was Director of Finance at Tularik Inc. prior to its acquisition by Amgen, Inc. in 2004. He began his career working in the audit practice for Ernst & Young LLP. Mr. Goeltz earned an M.B.A. from the UCLA Andersen School of Management and a B.B.A. in Business from Emory University. He is also a Certified Public Accountant (inactive).